To study the relative bioavailability of a single oral dose of imatinib mesylate tablets produced by Chongqing Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. and imatinib mesylate tablets (Gleevec?) produced by Novartis Pharmaceuticals AG, Switzerland, in healthy male subjects and to evaluate the bioequivalence of the two preparations.

Start Date-

Sponsor / Collaborator

Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

CTR20130555 / Completed

阿戈美拉汀片在健康男性受试者中的单次剂量、随机、开放生物等效性研究

[Translation] A single-dose, randomized, open-label bioequivalence study of agomelatine tablets in healthy male subjects

研究重庆福安药业集团庆余堂制药有限公司研制、生产的阿戈美拉汀片（25mg/片）和法国施维雅公司生产的阿戈美拉汀片（商品名：维度新，25mg/片）的相对生物利用度，评价两制剂间的生物等效性。

[Translation]

To study the relative bioavailability of agomelatine tablets (25 mg/tablet) developed and produced by Chongqing Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. and agomelatine tablets (trade name: Victorinox, 25 mg/tablet) produced by Servier, France, and to evaluate the bioequivalence of the two preparations.

Start Date20 Dec 2013

Sponsor / Collaborator

Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

CTR20130553 / Completed

甲磺酸伊马替尼胶囊在健康男性受试者中的单次剂量、随机、开放生物等效性研究

[Translation] A single-dose, randomized, open-label bioequivalence study of imatinib mesylate capsules in healthy male subjects

研究健康男性受试者单次口服由重庆福安药业集团庆余堂制药有限公司生产的甲磺酸伊马替尼胶囊和瑞士诺华制药有限公司生产的甲磺酸伊马替尼胶囊（格列卫）的相对生物利用度，评价两制剂间的生物等效性。

[Translation]

To study the relative bioavailability of a single oral dose of imatinib mesylate capsules produced by Chongqing Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. and imatinib mesylate capsules (Gleevec) produced by Novartis Pharmaceuticals AG in Switzerland in healthy male subjects and to evaluate the bioequivalence of the two preparations.

Start Date14 Aug 2013

Sponsor / Collaborator

Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

100 Clinical Results associated with Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

0 Patents (Medical) associated with Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

Literatures (Medical) associated with Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

31 Dec 2024·Pharmaceutical Biology

Shenxiang Suhe pill improves cardiac function through modulating gut microbiota and serum metabolites in rats after acute myocardial infarction

Article

Author: Zhao, Xin ; Wang, Xiaoying ; Sun, Congying ; Xie, Tian ; Wei, Xing ; Zhang, Zhaojian ; Wang, Kaiyue ; Zhu, Jiaming ; Yan, Junyuan ; Chen, Wei ; Zhong, Xinqin

CONTEXTShenxiang Suhe pill (SXSH), a traditional Chinese medicine, is clinically effective against coronary heart disease, but the mechanism of cardiac-protective function is unclear.OBJECTIVEWe investigated the cardiac-protective mechanism of SXSH via modulating gut microbiota and metabolite profiles.MATERIALS AND METHODSSprague-Dawley (SD) male rats were randomly divided into 6 groups (n = 8): Sham, Model, SXSH (Low, 0.063 g/kg; Medium, 0.126 g/kg; High, 0.252 g/kg), and Ato (atorvastatin, 20 mg/kg). Besides the Sham group, rats were modelled with acute myocardial infarction (AMI) by ligating the anterior descending branch of the left coronary artery (LAD). After 3, 7, 14 days' administration, ultrasound, H&E staining, serum enzymic assay, 16S rRNA sequencing were conducted to investigate the SXSH efficacy. Afterwards, five groups of rats: Sham, Model, Model-ABX (AMI with antibiotics-feeding), SXSH (0.126 g/kg), SXSH-ABX were administrated for 14 days to evaluate the gut microbiota-dependent SXSH efficacy, and serum untargeted metabolomics test was performed.RESULTS0.126 g/kg of SXSH intervention for 14 days increased ejection fraction (EF, 78.22%), fractional shortening (FS, 109.07%), and aortic valve flow velocities (AV, 21.62%), reduced lesion area, and decreased serum LDH (8.49%) and CK-MB (10.79%). Meanwhile, SXSH upregulated the abundance of Muribaculaceae (199.71%), Allobaculum (1744.09%), and downregulated Lactobacillus (65.51%). The cardiac-protective effect of SXSH was disrupted by antibiotics administration. SXSH altered serum metabolites levels, such as downregulation of 2-n-tetrahydrothiophenecarboxylic acid (THTC, 1.73%), and lysophosphatidylcholine (lysoPC, 4.61%).DISCUSSION AND CONCLUSIONThe cardiac-protective effect and suggested mechanism of SXSH could provide a theoretical basis for expanding its application in clinic.

01 Jul 2006·Journal of Biomedical ScienceQ2 · MEDICINE

Hepatoprotective effect of total flavonoids from Laggera alata against carbon tetrachloride-induced injury in primary cultured neonatal rat hepatocytes and in rats with hepatic damage

Q2 · MEDICINE

ArticleOA

Author: Hongtian Yao ; Longxi Lu ; Yu Zhao ; Xiumei Wu ; Qunxiong Zheng ; Fang Wang ; Changxin Zhou ; Yihang Wu

The hepatoprotective activities of total flavonoids of Laggera alata (TFLA) were evaluated by carbon tetrachloride (CCl(4))-induced injury in primary cultured neonatal rat hepatocytes and in rats with hepatic damage. In vitro, TFLA at a concentration range of 1-100 microg/ml improved cell viability and inhibited cellular leakage of two enzymes, hepatocyte aspartate aminotransferase (AST) and alanine aminotransferase (ALT), caused by CCl(4). In vivo, oral treatment with TFLA at doses of 50, 100, and 200 mg/kg significantly reduced the levels of AST, ALT, total protein, and albumin in serum and the hydroxyproline and sialic acid levels in liver. Histopathological examinations revealed that liver damage were improved when treated with TFLA. Meanwhile, 1,1-diphenyl-2-picrylhydrazyl (DPPH) and superoxide radicals scavenging activities of TFLA were also determinated. To understand the exact components of TFLA responsible for the hepatoprotective effect, nine flavonoid compounds were isolated and identified from TFLA. In conclusion, the present investigation was the first to verify the hepatoprotective effect of L. alata in vitro and in vivo. The hepatoprotective action of TFLA is likely related to its potent antioxidative and anti-inflammatory activity. Neutralizing reactive oxygen species by nonenzymatic mechanisms and enhancing the activity of original natural hepatic-antioxidant enzymes may be the main mechanisms of TFLA against CCl(4)-induced injury.

Zhongguo Xiandai Yingyong Yaoxue

Study on extraction process of polysaccharide from Caulis Dendrobii

Author: Qian, Ye ; Lv, Bu-wang

The extraction process of polysaccharide from Caulis Dendrobii was optimized using orthogonal design with the amount of polysaccharide determined by UV spectrophotometry as the indicator.The times of extracting, the amount of water and comminution degree influenced the extraction of polysaccharide significantly.The optimum extraction process of polysaccharide from Caulis Dendrobii was as follows, grind Caulis Dendrobii to obtain rough grains and add 20 times of water to extract 4 times with 8 h for each time.

100 Deals associated with Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

100 Translational Medicine associated with Hangzhou Huqingyutang Pharmaceutical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tonifying Kidney Pills	Kidney Diseases More	Approved
WeiFuChun	Stomach Cancer More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis